Adalbern (Imatinib)
Adalbern is an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.
Share Now
Additional Information
Name | Adalbern |
Description | is an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome. |
Active Ingredient | Imatinib |
Indication | Adalbern is indicated for the treatment of:
|
Strengths | 100 mg , 400 mg tablets |
Related Products
Related products
Azacitidine (Azadual)
Rated 0 out of 5Levaletrol (Letrozole) 2.5 mg
Rated 0 out of 5Litak® (Cladribine) – 2 mg/ml
Rated 0 out of 5Viatrinil 1mg/ml Solution For Injection, 5 Ampoules (Granisetron)
Rated 0 out of 5
Disclaimer
Pharma Solution is the marketing agent and Distributor for the listed products for the Gulf and MENA region. The products are either registered and approved by the respective local health authority or contracted by the MAH to supply to the end users on a named patient basis. Some products such as Orphan drugs, rare diseases medicines are imported based on special import permits and as per need of the Hospitals in compliance with full documentation.